VIVES is a multi-sector fund that invests in projects with a positive societal impact
In 1957 mankind sent the first object to Space in its goal to reach further. In the last 60 years the amount of man-made objects sent into Space has grown exponentially. However, most of these objects...
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
Spinovit, a UCLouvain spin-off, is developing a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction and prevent cardiovascular risks.
Cardio...
Philippe Mengal, past CEO Greenwatt :
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
Pierre Blondeau, CEO Upstreem :
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Vincent Mouret, Chairman of the board of Cissoid :
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years.
I have really appreciated VIVES involvement and...
Eligo welcomes genetic medicines leader Bobby Gaspar as chair of its board of directors
Oct 1, 2024
Dr. Gaspar brings invaluable expertise to gene-editing pioneering company Eligo as it prepares
Generare raises €5m to scale the discovery of new medicines and molecules hiding in microbes
BiocSol secures €5.2M seed funding to transform sustainable crop protection with next generation microbial-based solutions, targeting total €10M in funding by year-end